bisphosphonate-associated osteonecrosis jaw report task force american society bone mineral research pubmed ncbi abstract onj increasingly suspected potential complication bisphosphonate therapy recent years asbmr leadership appointed multidisciplinary task force address key questions related case definition epidemiology risk factors diagnostic imaging clinical management future areas research related disorder report summarizes findings recommendations task force introduction increasing recognition bisphosphonates osteonecrosis jaw onj led leadership american society bone mineral research asbmr appoint task force address number key questions related disorder materials methods multidisciplinary expert group reviewed pertinent published data bisphosphonate-associated onj food drug administration drug adverse event reports reviewed results conclusions case definition developed subsequent studies report condition task force defined onj presence exposed bone maxillofacial region heal num wk identification health care provider based review published unpublished data risk onj oral bisphosphonate therapy osteoporosis low estimated num num num num patient-treatment years task force recognized information incidence onj rapidly evolving true incidence higher risk onj patients cancer treated high doses intravenous bisphosphonates higher range num num patients depending duration therapy future improved diagnostic imaging modalities optical coherence tomography mri combined contrast agents manipulation image planes identify patients preclinical early stages disease management largely supportive research agenda aimed filling considerable gaps knowledge disorder outlined 
